Clinical Trial Update: Post-Market Real-World Evidence Registry for the NeuroOne OneRF® Ablation System for Epilepsy

View source ↗

Summary

A post-market real-world evidence registry is planned to evaluate the NeuroOne OneRF ablation system for epilepsy; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Snippet

Sponsor: NeuroOne Medical Technologies Corporation | Conditions: Drug Resistant Epilepsy, Refractory Epilepsy | Status: NOT_YET_RECRUITING